|
Patient Physician Communication, A Nasal Diuretic, and Pharma Ads
September 18, 2025
|
|
|
|
|
Together with
|
|
|
|
“I know of few remedies more powerful than a carefully chosen word. Patients crave caring, which is dispensed largely with words. Talk, which can be therapeutic, is one of the underrated tools in a physician’s armamentarium.”
|
|
Bernard Lown, MD
|
|
|
|
Cardiovascular risk communication might be failing patients when they need it most, after the HARIPA study revealed significant disconnects between patient and physician perceptions of future cardiovascular risk and procedural complications.
- Effective risk communication is essential for cardiovascular disease management as the leading cause of global mortality, supporting decision-making and treatment adherence.
- Gaps between what physicians say and what patients hear can weaken therapy compliance and health outcomes making communication a quality-of-care issue.
The HARIPA study surveyed cardiology inpatients and their physicians from October 2022 to March 2023, using structured questionnaires to assess risk perception and communication quality, revealing some serious misalignments…
- Agreement between patients and physicians regarding future cardiovascular risk was poor (0.29 agreement level), with patients often underestimating true risk levels.
- Patient understanding of procedural risks showed only moderate agreement (0.34).
- Despite communication failures, 76.9% of patients reported feeling adequately informed about procedural risks, suggesting overconfidence in risk understanding.
- Among the 208 patients who experienced complications, 69.3% stated they had not been warned about the complications they developed.
Researchers also revealed that a patient’s perceived level of understanding doesn’t translate to actual risk comprehension or preparedness for potential outcomes.
- The most common admission diagnosis was ischemic heart disease (41.3%), representing patients at particularly high risk for future cardiovascular events.
- The study’s multicenter design across 28 hospitals also suggests these communication gaps are systemic rather than isolated institutional problems.
Given that well-informed patients demonstrate better adherence to preventive therapies, addressing these communication failures represents both a patient safety problem and an opportunity to improve long-term cardiovascular outcomes.
- For example, physicians can tailor communication strategies to individual patient characteristics with the goal of improving both understanding and health outcomes.
- However, it’s worth noting that patients often underestimate the likelihood of their own mortality, which effective communication may never change.
The Takeaway
The HARIPA study exposes a paradox in cardiovascular care because while patients feel adequately informed about their risks, they consistently underestimate future cardiovascular danger and remain unprepared for complications. Where it gets trickier is also understanding that even perfect physician communication might not change a patient’s bad habits or put them in touch with reality.
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
Explore Vitrea Advanced Visualization
Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
- Aditum and Mabwell Launch Kalexo: Venture capital firm Aditum Bio partnered with China’s Mabwell Bioscience to launch Kalexo Bio with a focus on cardiovascular disease. Aditum paid $12M upfront and up to $1B in future payments for exclusive global licensing rights to Mabwell’s dual-target siRNA candidate 2MW7141, which aims to treat elevated cholesterol and prevent ASCVD. The preclinical siRNA showed potent target gene suppression with minimal off-target effects, potentially competing with Novartis’s Leqvio in cholesterol management.
- Artrya’s Salix Funding: CCTA AI startup Artrya completed a $53M ($80M AUD) follow-on equity offering to support the U.S. launch of its FDA-approved Salix platform for coronary plaque detection. The fundraising comes just a few months after Salix’s FDA clearance, making Artrya yet another competitor in the rapidly growing CCTA AI plaque detection segment. The funding is also another sign of investors’ faith in CCTA AI startups, which continue to raise sizable rounds (and hefty IPOs), while investments in other imaging AI segments have slowed.
- Innovaccer’s New Story: Innovaccer acquired Story Health, an AI-powered cardiovascular care platform to advance its goal of streamlining specialty medicine workflows. Founded by Google veterans in 2020, Story Health’s platform achieved impressive results: 6.9% 30-day heart failure readmission rates versus 18.1% national average, and 60% reduction in hospitalizations. The acquisition strengthens Innovaccer’s Healthcare Intelligence Cloud, enabling health systems to scale specialty care capacity while reducing clinician burden through AI-assisted continuous patient engagement.
- AccurKardia’s AK+ Guard Shines: AccurKardia made big waves this week with a recent award nomination and a new pilot trial announcement. First, the company’s AK+ Guard technology for remote hyperkalemia detection via Lead I ECG was named a 2025 Digital Health Awards Quarterfinalist in Best in Class, AI in Patient Care. Second, the company launched its clinical pilot trial of AK+ Guard which will evaluate over 150 patients across inpatient, outpatient, and home settings. AK+ Guard is compatible with consumer wearables and previously achieved 89% accuracy in validation studies.
- FDA Recalls BSCI Reliance: The FDA issued three Class I recalls for Boston Scientific Reliance defibrillation leads due to rising low-voltage shock impedance risks. The affected Reliance leads with ePTFE coating, manufactured 2002-2021, can become less effective over time due to tissue ingrowth and calcification. As of July, this issue was linked to 386 serious injuries and 16 deaths. According to the FDA, healthcare providers should monitor lead impedance and replace leads exceeding 150 ohms to prevent defibrillation failures and patient death.
- ASNC Stands Up to Reimbursement Cuts: The American Society of Nuclear Cardiology advocated against the proposed 57% Medicare reimbursement cut for cardiac amyloidosis imaging. The 2026 reduction would slash payments from $1,300 to $558 per exam due to CPT code 78803’s reassignment to a lower-paying category. The ASNC’s President-elect warned that this threatens access to potentially life-saving diagnostics for an underdiagnosed disease with effective therapies. The timing is also concerning as demand grows for earlier screening, making the lengthy SPECT imaging financially unviable for hospitals.
- AI Automates Echo Evaluation: Cardiologists developed EchoNet-Measurements, an open-source AI model that accurately evaluates 18 echocardiographic parameters automatically. Published in JACC, the deep learning model was trained on over 150k transthoracic echocardiography studies from Cedars-Sinai and validated externally using Stanford Healthcare data achieving a mean coverage probability of 0.79 to 0.84 depending on the doppler type. The model addresses echocardiography’s time-consuming manual measurement burden and high variability between experts.
- Diuretic Nasal Spray: The FDA approved Corstasis Therapeutics’s ENBUMYST (bumetanide nasal spray) for treating edema associated with congestive heart failure, liver disease, and kidney disease in adults. The self-administered nasal spray demonstrates rapid absorption and predictable diuretic response similar to IV bumetanide, bridging the gap between oral and IV diuretics. ENBUMYST also helps address an unmet need since fluid overload causes over 1 million annual hospitalizations. Corstasis plans ENBUMYST’s U.S. launch in Q4 2025, targeting a multi-billion-dollar market opportunity.
- CHIP Increases Myocarditis Risk: A recent UK Biobank study suggests that clonal hematopoiesis of indeterminate potential (CHIP) could substantially increase a patient’s risk of myocarditis/pericarditis. Among the study’s 335k participants, those with any CHIP (11k) faced a hazard ratio of 1.75 and those with large CHIP showed a 2.07 HR for developing inflammatory heart disease. CHIP also increased risk of other immune-mediated inflammatory diseases, meaning it could be a potential treatment target for inflammatory cardiac conditions.
- Pharma Ads Threaten Trust: A longitudinal survey in JAMA Health Forum put a spotlight on physicians’ evolving perception of pharma marketing. Researchers surveyed over 5k medical students in 2011, then 1.1k of the same trainees in 2024, finding that they were almost 3x more likely to agree that trust in medicine is threatened by the pharma industry’s marketing influence (5.6% vs. 14.5%). The poll showed increased agreement that med schools shouldn’t allow pharma to interact with students (59.6% vs. 72.2%), although it also found that more physicians believe they can receive useful drug info from marketing (66.3% vs. 76.9%).
- Peerbridge Peers Ahead: Peerbridge Health closed a $7M funding round to continue its mission of expanding access to affordable cardiac diagnostics through its Cor MDx remote monitoring device. The Cor MDx offers high-fidelity, real-time cardiac monitoring using ECG signals and Peerbridge also recently submitted the wearable monitor for FDA 510(k) clearance. To prepare for potential clearance and commercialization, Peerbridge expanded its sales team across three regions, targeting primary care and cardiology clinics with hospital-grade cardiac monitoring.
|
|
Personalized Plaque Analysis Now With Medicare Coverage
Heartflow’s Plaque Analysis is now reimbursable thanks to Medicare’s new coverage for AI-enabled plaque analysis of eligible patients with coronary artery disease.
|
|
GLS Analysis of Us2.ai’s Fully-Automated Software
Ten years after the first head-to-head comparison of 2D echocardiography, the latest review suggests Us2.ai is among the easiest to use and integrate. Read the study to learn about how Us2.ai’s software requires zero operator input, operates without human intervention, and leads to high agreement with traditional semi-automated speckle- tracking software solutions.
|
|
New Horizons in Structural Heart
TAVR and TMVR rates are rising rapidly, placing more pressure on interventional planning. Tune into this Circle CVI and Radcliffe Cardiology breakout detailing how to leverage modern CT workflows to produce efficient and accurate pre-procedural plans.
|
|
- Why Competitors Benchmark Against Monebo’s ECG Algorithm: In the world of cardiac monitoring, it’s a big deal when your competitors use your technology as their benchmark for success. Learn why Monebo Technologies’ ECG analysis algorithm has been the “predicate device” of at least 13 other companies FDA 510(k) clearance regulatory filings and what this means for providers and their patients.
- Siemens Healthineers ACUSON Origin Ultrasound System is Redefining CVUS: ACUSON Origin meets the demands of today’s cardiovascular care with AI-powered efficiency across adult and pediatric echo, vascular, structural heart, and EP. Streamlined workflows, intuitive walk-up usability, and advanced ergonomics empower clinicians to deliver confident, high-quality care—supporting a wide range of complex cases and clinical applications.
- Merge and Duly Health Streamline Cardiology Reporting: Over the last 10 years, Dr. Sujith Kalathiveetil of Duly Health and Care has seen a significant evolution in cardiovascular imaging and experienced a similar evolution with Merge’s cardiology solutions. See how Merge Cardio has helped make cardiology reporting more consistent, accurate, and easier to obtain for Dr. Kalathiveetil and his colleagues.
- Vista AI Grows CMR Volume: Are your patients waiting weeks or months for cardiac MRIs? See Brigham and Women’s Hospital’s real-world results showing how Vista AI’s software for automated MRI scanning led to 50% more scan slots, without adding more scanners or staff.
|
|
|
|
|
